Fox Run Management L.L.C. Acquires 2,830 Shares of Ascendis Pharma A/S $ASND

Fox Run Management L.L.C. lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 169.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,496 shares of the biotechnology company’s stock after purchasing an additional 2,830 shares during the quarter. Fox Run Management L.L.C.’s holdings in Ascendis Pharma A/S were worth $959,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Rhumbline Advisers boosted its stake in shares of Ascendis Pharma A/S by 4.0% during the 2nd quarter. Rhumbline Advisers now owns 1,441 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 55 shares during the period. Certuity LLC boosted its stake in shares of Ascendis Pharma A/S by 5.7% during the 4th quarter. Certuity LLC now owns 1,170 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 63 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 15.1% during the 4th quarter. Farther Finance Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 72 shares during the period. Jones Financial Companies Lllp boosted its stake in shares of Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 83 shares during the period. Finally, New Wave Wealth Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 3.7% during the 4th quarter. New Wave Wealth Advisors LLC now owns 2,518 shares of the biotechnology company’s stock worth $537,000 after acquiring an additional 89 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on ASND shares. Barclays lifted their target price on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a research note on Monday, May 11th. Morgan Stanley reaffirmed an “overweight” rating and issued a $256.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, February 12th. Wolfe Research reaffirmed an “outperform” rating and issued a $260.00 target price on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Citigroup initiated coverage on Ascendis Pharma A/S in a research report on Monday, May 18th. They issued a “buy” rating and a $355.00 target price on the stock. Finally, Wells Fargo & Company decreased their target price on Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average price target of $295.39.

Insider Activity at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime purchased 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the transaction, the director directly owned 400 shares of the company’s stock, valued at $95,120. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. Additional details regarding this sale are available in the official SEC disclosure. 40.00% of the stock is currently owned by corporate insiders.

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $209.79 on Thursday. Ascendis Pharma A/S has a 12 month low of $160.86 and a 12 month high of $250.74. The stock’s 50 day moving average is $232.61 and its 200-day moving average is $223.58. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of 24.20 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. Equities research analysts expect that Ascendis Pharma A/S will post 12.85 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.